A combination assay for simultaneous assessment of multiple signaling pathways.
We have developed an assay in which modulation of two or more signaling pathways can be assessed concurrently by combining reporter gene systems with fluorescent probe technology. The validation of this method was achieved by indirect analysis of adenylyl cyclase activation with the use of a cyclic AMP response element (CRE)-luciferase reporter system in combination with the measurement of calcium mobilization by Calcium Green-1 AM fluorescence on a fluorescent imaging plate reader. To demonstrate the utility of the method in studying the pharmacology of receptors that couple to more than one G protein, Chinese hamster ovary (CHO) cells, which stably expressed both the CRE-luciferase reporter gene and the human pituitary adenylyl cyclase-activating peptide (PACAP) receptor, were treated with PACAP 1-27 and 1-38. Calcium mobilization and the induction of adenylyl cyclase activity in response to each concentration of peptide were assessed in individuals wells. This assay may also be used to screen for ligands of two or more unrelated receptors simultaneously without compromising the assessment of either signaling pathway. To illustrate this point, Rat-1 fibroblasts, which expressed human alpha1A receptors, were cocultured with CRE-luciferase CHO cells, which expressed human GLP-1 receptors. Calcium mobilization elicited by phenylephrine agonism of the alpha1A receptor was assessed in the same assay as GLP-1-induced activation of adenylyl cyclase. The pEC(50) for each agonist was similar to that observed when the cell lines were not cocultured. The number of different receptors that can be screened per well is limited only by the ability to distinguish different reporter gene signals and fluorescent indicators.
Goetz
A S
AS
Department of Receptor Biochemistry, Glaxo Wellcome Research and Development, 5 Moore Drive, 3.2054, Research Triangle Park, NC 27709, USA.
Liacos
J
J
Yingling
J
J
Ignar
D M
DM
D000262:Adenylyl Cyclases / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D016466:CHO Cells; D002116:Calcitonin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D005576:Colforsin / Q000494:pharmacology; D006224:Cricetinae; D000242:Cyclic AMP / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004790:Enzyme Induction; D005456:Fluorescent Dyes / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000187:drug effects / Q000378:metabolism*; D017930:Genes, Reporter / Q000502:physiology*; D006801:Humans; D008156:Luciferases / Q000494:pharmacology; D009479:Neuropeptides / Q000494:pharmacology; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D051381:Rats; D011955:Receptors, Drug; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
C495401:ADCYAP1 protein, human; C495403:Adcyap1 protein, rat; D005456:Fluorescent Dyes; D009479:Neuropeptides; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D011955:Receptors, Drug; D005576:Colforsin; D002116:Calcitonin; D000242:Cyclic AMP; D008156:Luciferases; D019204:GTP-Binding Proteins; D000262:Adenylyl Cyclases; D002118:Calcium